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PI3Kd and PI3Kg regulate immune cell signaling,
while the related PI3Ka and PI3Kb regulate cell
survival and metabolism. Selective inhibitors of
PI3Kd/g represent a potential class of anti-inflamma-
tory agents lacking the antiproliferative effects asso-
ciated with PI3Ka/b inhibition. Here we report the
discovery of PI3Kd/g inhibitors that display up to
1000-fold selectivity over PI3Ka/b and evaluate
these compounds in a high-content inflammation
assay using mixtures of primary human cells. We
find selective inhibition of only PI3Kd is weakly anti-
inflammatory, but PI3Kd/g inhibitors show superior
inflammatory marker suppression through suppres-
sion of lipopolysaccharide-induced TNFaproduction
and T cell activation. Moreover, PI3Kd/g inhibition
yields an anti-inflammatory signature distinct from
pan-PI3K inhibition and known anti-inflammatory
drugs, yet bears striking similarities to glucocorticoid
receptor agonists. These results highlight the poten-
tial of selectively designing drugs that target kinases
with shared biological function.
INTRODUCTION
Inflammatory disorders such as rheumatoid arthritis represent an
important target for drug development. Therapies include nap-
roxen, indomethacin (Backhouse et al., 1980), and corticoste-
roids (Gray et al., 1991). Although effective, these agents have
significant side effects that limit their utility (Gray et al., 1991;
Rainsford, 1993). More recently, antibody therapeutics directed
against tumor necrosis factor a (TNFa) have become useful for
treatment of refractory chronic inflammation (Feldmann, 2002;
Feldmann and Maini, 2001). These agents reduce inflammation
and slow disease progression (Feldmann, 2002; Feldmann and
Maini, 2001; Imperato et al., 2004), but are expensive and canChemistry & Biology 17, 123generate immune-related side effects, including infection and
lymphoma emergence (Imperato et al., 2004).
Recently, targeted inhibitors of the phosphoinositide-3-kinase
(PI3K) pathway have been suggested as immunomodulatory
agents (Hirsch et al., 2008; Rommel et al., 2007). This interest
stems from the fact that the PI3K pathway serves multiple func-
tions in immune cell signaling, primarily through the generation of
phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a membrane-
bound second messenger (Cantley, 2002; Deane and Fruman,
2004; Hirsch et al., 2008; Katso et al., 2001). PIP3 recruits
proteins to the cytoplasmic side of the lipid bilayer, including
protein kinases and GTPases (Cantley, 2002; Hirsch et al.,
2008; Katso et al., 2001), initiating a complex network of down-
stream signaling cascades important in the regulation of immune
cell adhesion, migration, and cell-cell communication.
The four class I PI3K isoforms differ significantly in their tissue
distribution. PI3Ka and PI3Kb are ubiquitous and activated
downstream of receptor tyrosine kinases (RTK) (Hirsch et al.,
2008; Katso et al., 2001), whereas PI3Kd and PI3Kg are primarily
limited to hematopoietic (Deane and Fruman, 2004; Rommel
et al., 2007) and endothelial cells (Puri et al., 2004, 2005), and
are activated downstream of RTKs, and G protein coupled
receptors (GPCR), respectively (Katso et al., 2001). Mouse
genetic studies have revealed that PI3Ka andPI3Kb are essential
for normal development (Vanhaesebroeck et al., 2005), whereas
loss of PI3Kd and/or PI3Kg yields viable offspring with selective
immune deficits (Okkenhaug and Vanhaesebroeck, 2003; Swat
et al., 2006; Vanhaesebroeck et al., 2005; Webb et al., 2005).
The expression pattern and functions of PI3Kd and PI3Kg have
generated much interest in developing PI3Kd/g inhibitors as
agents for many diseases, including rheumatoid arthritis, aller-
gies, asthma, chronic obstructive pulmonary disease and mul-
tiple sclerosis (Hirsch et al., 2008; Marone et al., 2008; Rommel
et al., 2007; Ruckle et al., 2006). Studies using both pharmaco-
logic and genetic methods have shown these two isoforms often
demonstrate synergistic interactions with each other (Konrad
et al., 2008; Laffargue et al., 2002). In mast cells, for example,
PI3Kd is essential for degranulation in response to IgE cross-
linking of Fc-receptors (Ali et al., 2004; Ali et al., 2008), but
PI3Kg plays an important role in amplifying the response–134, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 123
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cellular functions, including lymphocyte homing (Reif et al., 2004)
and the neutrophil respiratory burst (Condliffe et al., 2005), where
PI3Kg plays a critical role and PI3Kd amplifies each process.
The nonredundant but related roles of PI3Kd and PI3Kg have
made it difficult to determine which of the two isoforms (alone
or in combination) is best targeted in a particular inflammatory
disorder. Studies using mice that lack PI3Kd and/or PI3Kg or
express kinase-dead variants of PI3Kd and PI3Kg have been
valuable tools in understanding their roles. For example, PI3Kd
knockout mice demonstrated diminished neutrophil chemotaxis
(Puri et al., 2004), diminished antibody production (both T cell
dependent and independent) (Jou et al., 2002), and lower
numbers of mature B cells (Clayton et al., 2002; Jou et al.,
2002), and a decrease in their proliferation in response to anti-
IgM (Jou et al., 2002) . This phenotype was replicated in the
PI3Kd kinase-dead variant (Okkenhaug et al., 2002), and with
PI3Kd selective inhibitors (Ali et al., 2004; Puri et al., 2004; Sadhu
et al., 2003), along with decreased numbers of and proliferation
of mast cells, and an attenuated allergic response (Ali et al.,
2004). The PI3Kg knockout contained higher numbers of, but
less responsive, neutrophils (Hirsch et al., 2000), lower numbers
of and less responsive macrophages (Hirsch et al., 2000) and
dendritic cells (Del Prete et al., 2004), displayed decreased
mast cell degranulation (Laffargue et al., 2002), a higher ratio of
CD4+ to CD8+ T cells (Rodriguez-Borlado et al., 2003), increased
thymocyte apoptosis (Sasaki et al., 2000), diminished induction
of CXCR3 on activated T cells (Barbi et al., 2008), and decreased
cardiac contractility (Crackower et al., 2002). This latter effect on
cardiac tissue was a concern for chronic dosing of patients with
PI3Kg inhibitors. However, this concern was largely mitigated
when the PI3Kg kinase-dead variant (which better mimics inhibi-
tion of the kinase rather than loss of the protein) showed similar
immune cell phenotypes, but importantly had no cardiac defects
(Patrucco et al., 2004). The cardiac effect was later shown to be
due to scaffolding effects rather than the catalytic activity of
PI3Kg. The dual PI3Kd /PI3Kg knockout was viable but exhibited
serious defects in T cell development (Webb et al., 2005) and
thymocyte survival (Swat et al., 2006). The PI3Kg knockout/
PI3Kd kinase-dead combination produced a similar phenotype
suggesting that at least within the immune system, the role of
PI3Kd is likely only a catalytic one (Ji et al., 2007).
Interpretation of studies using knockout and kinase-dead
mice can be challenging because these models provide only a
steady-state picture of the immune system, lack temporal and
dose control, and do not permit a full understanding of how
a dynamic immune response will react to reversible inhibition.
Selective inhibitors with varying profiles (PI3Kd, PI3Kg, and
PI3Kd/g) are necessary for studies of leukocyte signaling in order
to assess the relative contributions of each PI3K to immune cell
activation.
The key challenge in developing isoform selective PI3K inhib-
itors is that all class I PI3Ks share nearly identical ATP binding
pockets (Knight et al., 2004). However, we and others reported
that a quinazolinone-based chemical scaffold binds PI3Kd with
high selectivity (Knight et al., 2006; Puri et al., 2004). This chemo-
type exploits a unique, noncatalytically active conformation of
PI3Kd (and PI3Kg) that is not easily adopted by PI3Ka and
PI3Kb (Berndt et al., 2010; Knight et al., 2006). In this work, we124 Chemistry & Biology 17, 123–134, February 26, 2010 ª2010 Elsereport the development of potent PI3Kd and PI3Kd/g inhibitors.
We then characterize these compounds using primary human
leukocytes stimulated in coculture with different cytokine and
chemokine ligands in order to determine if targeting PI3Kg and
PI3Kd, either alone or in combination, results in a distinct anti-
inflammatory fingerprint. Finally, we compare selective PI3Kd/g
inhibitors to other kinase inhibitors and clinical anti-inflammatory
therapeutics.
RESULTS
Design of PI3Kd and PI3Kd/g Inhibitors
The ATP-binding pocket of the four class I PI3Ks (a, b, d, g)
contains three distinct inhibitor binding elements: a hinge region
with two hydrogen bonding contacts, a hydrophobic pocket
deep in the protein not occupied by ATP, and a conformationally
mobile methionine residue above the adenine ring of ATP (Knight
et al., 2006) (Figure 1). The first two binding elements are
common to all PI3Ks whereas the third appears to be signifi-
cantly accessible by only PI3Kd and PI3Kg (Berndt et al., 2010;
Knight et al., 2006).
In order to maximize the differential binding to PI3Kd or PI3Kg
compared with PI3Ka and PI3Kb, we exploited the rearrange-
ment of Met804, which normally forms the roof of the ATP-
binding pocket when PI3Kg is bound to ATP and pan-PI3K inhib-
itors (Figure 1A, left panel). This rearrangement reveals a new
pocket, not found in any ATP bound forms of PI3Ks (Knight
et al., 2006). The aryl quinazolinone inhibitor, PIK39 (Figure 1A,
right panel), exists in a conformation which projects the quinazo-
linone moiety into the pocket produced by the Met804 move-
ment, affording highly selective binding to PI3Kd and PI3Kg
(Berndt et al., 2010; Knight et al., 2006).
Synthesis and Biochemical Characterization
Both PIK39 (Figure 1A, right panel) and the related PIK293
(Figure 1B) form hydrogen bonds with the hinge region of
PI3Ks, but do not contain elements that project into the deeper
hydrophobic pocket (Knight et al., 2006) (Figure 1B). Despite
the sequence similarities in the hydrophobic binding pocket,
we reasoned that it was possible to distinguish between PI3Kd
and PI3Kg with the appropriate binding elements. PIK293 was
therefore diversified into two series using palladium-catalyzed
routes (Figure 1C). Series 1, synthesized with Suzuki couplings,
projected substituted aryl rings into the affinity pocket, while
series 2 placed sterically minimal alkyne derivatives into the
affinity pocket using Sonogashira couplings (see Figures S1
and S2 available online).
Nearly 50 candidate inhibitors were synthesized and screened
against all class I PI3Ks as previously described (Knight et al.,
2007). As expected, all compounds were highly selective for
PI3Kd over PI3Ka and PI3Kb (Figures S1 and S2). Addition of
elements that interacted with the hydrophobic-affinity pocket
increased potency against PI3Kd and PI3Kg without compro-
mising selectivity against PI3Ka and PI3Kb. SW18, one of the
most potent PI3Kd inhibitors in the series (Figures 2A and 2B),
was screened against 219 protein kinases at a concentration
of 10 mM. Two hundred eighteen kinases in the panel retained
at least 75% activity, and only one, macrophage stimulating 1
receptor (MST1R) kinase, was inhibited to less than 60% activityvier Ltd All rights reserved
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C
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Figure 1. Basis of Selectivity and Potency
for Aryl Quinazolinones
(A) Crystal structure of PI3Kg with PIK90, a pan-
PI3K inhibitor (Left) and PIK39, a PI3Kd inhibitor
(Right) (Knight et al., 2006). The biplanar binding
mode of PIK39 and alternate positioning of
Met804 (red) are illustrated. Chemical compound
structures are shown below.
(B) Compounds in this study introduce affinity
elements (yellow) onto selective tolyl quinazoli-
none (red) scaffold maintaining selectivity for
PI3Kg and PI3Kd.
(C) Diversification of SW series affinity elements
was achieved through Suzuki-Miyaura couplings
with aryl boronic acids and Sonogashira couplings
with terminal alkynes, yielding two distinct chemi-
cal series.
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moiety responsible for selectivity within the PI3K family also
confers selectivity against protein kinases.
Phenol containing members of Series 1 showed the greatest
potency against PI3Kd (Figures 2A and 2B), and tuning of
PI3Kg affinity was possible by substitution of the phenol ring at
the 4 position (SW14, Figures 2A and 2B). Movement of the
fluoro-substituent to the 5 position (SW13) afforded the most
potent PI3Kd inhibitor reported to date. Although there is consid-
erable precedent for hydroxyl groups in the hydrophobic affinity
pocket of PI3Ks (Palanki et al., 2007; Walker et al., 2000),
phenolic substituents are often subject to first-pass metabolism,
limiting their oral bioavailability. We therefore explored groupsChemistry & Biology 17, 123–134, February 26, 2010that would preserve hydrogen-bonding
interactions but would not contain a
phenol. Of the several candidate mole-
cules prepared, only the indole-sub-
stituted SW19 was able to retain signifi-
cant PI3Kd potency and some activity
against PI3Kg while eliminating the pres-
ence of a hydroxyl group (Figure 2B).
Introducing an aryl-alkynyl linkage in
Series 2 reduced the bulk of the affinity
pocket binding element and decreased
PI3Kg inhibition, resulting in selectivity
for PI3Kd (Figure S2). As in Series 1, a pro-
perly positioned hydroxyl group was crit-
ical to maintain potency against PI3Kd.
For example, SW30 contained a hydroxy-
methyl-substituted alkynewhereas SW41
extended the hydroxyl group by one
methylene unit and resulted in > 30-fold
loss of binding affinity for PI3Kd (Fig-
ure S2). Together, these structure-
activity data suggest that potency against
PI3Kd requires the presence of a pro-
perly positioned hydrogen bond donor/
acceptor and that the additional bulk
provided by aryl groups in Series 1
affords activity against PI3Kg (Figure 2C).
The PI3Kg/d ratio of these compounds
illustrates a wide range of biochemicalactivity against PI3Kg while preserving potency against PI3Kd.
Out of nearly 50 compounds, SW13, SW14, SW19, and SW30
(Figures 2 and 3) were selected for characterization in cellular
assays based on potency for PI3Kd and PI3Kg and their range
of selectivity between the two targets.
Cellular Signaling Effects
We next assessed the inhibition of PI3Kd and PI3Kg in a cell
model with a single readout by stimulating THP-1 monocytes
with different ligands to activate either PI3Kd or PI3Kg. Macro-
phage colony stimulating factor (M-CSF/CSF-1) is a cytokine
that binds to the M-CSF receptor activating RTK-linked PI3Ks
(Kelley et al., 1999), whereas the chemokine monocyteª2010 Elsevier Ltd All rights reserved 125
AB
C
Figure 2. Diversification of Tolyl Quinazolinone
Series
(A) Introduction of affinity elements to PIK293. Series 1
(PI3Kd/g) introduces aryl groups and Series 2 (PI3Kd) intro-
duces alkynyl-linked groups. IC50s of both Series 1 (blue)
and Series 2 (red) were graphed.
(B) Biochemical IC50s and g/d ratios for Series 1 and 2
along with benchmark compounds. All compounds were
tested at 10 mM ATP.
(C) Crystal structure of SW13 (cyan), and SW30 (pink) as
reported (Berndt et al., 2010). Hydrogen bonding elements
for SW series are all aligned.
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Figure 3. Effect of Selected Compounds on THP-1
Monocyte Signaling
(A) THP-1 monocyte signaling pathway leads to phosphorylation
of Akt through either RTK-linked macrophage colony stimulating
factor (M-CSF) or GPCR-linked monocyte chemoattractant
protein 1 (MCP-1).
(B) pAkt was measured by FACS using fluorescent pSer473 Akt
antibodies. Quantitated fluorescence was used to determine an
EC50 for selected compounds. Biochemical g/d ratios are provided
for comparison.
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a GPCR (Jones et al., 2003). Both stimuli lead to phosphorylation
of Akt at Ser473 (Camps et al., 2005; Jones et al., 2003; Pomel
et al., 2006), which we monitored by fluorescence-activated
cell sorting (FACS) (Figure 3A). We included a literature bench-
mark compound, AS605240 (Camps et al., 2005; Pomel et al.,
2006), and negative control (SW23) in our analysis.
M-CSF stimulated Ser473 p-Akt production was potently
blocked by SW13, SW14, SW19, and SW30, but not by SW23
or AS605240 (Figure 3B). We attribute these effects to PI3-Kd
inhibition because SW23 and AS605240, which do not signifi-
cantly inhibit PI3Kd at the doses tested, were ineffective. Only
the compounds with biochemical IC50 values under 25 nM
against PI3Kd were able to inhibit Ser473 p-Akt production in
this assay. Further support for the role of PI3Kd in this assay
comes from the consistent rank order (biochemical IC50 versus
cellular EC50). SW13 was most potent in the biochemical assay
and was the most potent in the cellular M-CSF assay as well.
MCP-1 stimulated Ser473 p-Akt production was blocked by
AS605240 and SW14, but not significantly by SW30 or SW23.
SW19 blocked MCP-1 stimulated Ser473 p-Akt production but
only at somewhat higher concentrations, in a manner consistent
with its biochemical IC50 value (Figure 3B). SW14, the most
potent tolyl quinazolinone PI3Kg inhibitor in the biochemical
assays, was of equal potency with AS605240, the most potent
PI3Kg inhibitor included in our studies. Similar to the M-CSF
assay, this rank order is consistent with the biochemical potency
of these compounds against PI3-Kg. The PI3Kd selectivity of
SW13 and especially SW30 is highlighted by their low activityChemistry & Biology 17, 123–134, Febrin this assay, whereas the inability of SW23 to inhibit
p-Akt formation suggests that the activity in this assay
is due to inhibition of PI3K rather than chemotype/scaf-
fold-dependent effects.
Modulation of Inflammatory Signaling in Human
Peripheral Blood Mononuclear Cells (PBMCs)
and Umbilical Vein Endothelial Cells (HUVECs)
The above cellular data motivated us to assess the role
of PI3Kd and PI3Kg in inflammatory signaling by use
of cocultures of primary human cells not adapted to
long-term growth in vitro. There are two advantages
of this approach. First, human cells rather than rodent
cells are used, permitting an accurate assessment of
human PI3K immune signaling. Second, the in vitro
nature of the assay allows use of the compounds
with highly distinct inhibitory profiles and minimizes
any pharmacokinetic/pharmacodynamic issues thatarise in the transition from cell-based to animal-based models.
We compared the activity of selective and pan-PI3K inhibitors
using the biologically multiplexed activity profiling (BioMAP)
method (Berg et al., 2006; Kunkel et al., 2004). This assay utilizes
primary human cells (HUVECs alone or in combination with
PBMCs), stimulated with combinations of inflammatory signals
(IL-1b, TNFa, IFN-g, IL-4, histamine, lipopolysaccharide [LPS],
and superantigen) (Figure 4A). The resultant expression levels
of a panel of 20 receptors, cytokines, cell adhesion molecules
and second messengers (Figure 4A) – were measured following
stimulation and drug treatment, and compared to the untreated
(‘‘no drug’’) levels. These expression levels yield a distinctive
pattern, or profile, unique to each drug that can be used to
compare and contrast several types of chemical compounds
and drug classes (Figure 4B). Similar profiles are generally
observed with similar mechanisms of action, but can also be
observedwhen different chemical compounds share a functional
similarity.
We evaluated pan-PI3K (a,b,d,g) inhibition and PI3Kg inhibi-
tion using PIK90 and AS605240 as benchmark compounds,
whereas PI3Kd inhibition and dual PI3Kd/g inhibition were evalu-
ated using SW30 and SW14, respectively. Each compound was
tested at a range of concentrations (Figure 4B) in order to identify
potential off-target activities at higher doses. For each marker
analyzed, a log10 ratio for drug- treated protein levels versus
0.1% dimethyl sulfoxide (DMSO)-treated cells is indicated
(Figure 4B). A log10 ratio of 1.0 indicates a 10-fold decrease
in protein level upon treatment with drug as compared with the
levels with 0.1% DMSO. The 0.1% DMSO measurement,uary 26, 2010 ª2010 Elsevier Ltd All rights reserved 127
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Figure 4. BioMAP Analysis of PI3K Inhibitors
(A) BioMAP systems details.
(B) BioMAP profiles for PIK90 (pan-PI3K) (top), SW30 (PI3Kd) (middle), and SW14 (PI3Kd/g) (bottom). Red dots represent a 10 mM dose, orange corresponds to
3.3 mM, yellow represents 1.1 mM, and green represents 370 nM. Levels of proteins were measured by ELISA and presented as log expression ratios (log10[para-
meter value with inhibitor/parameter value of 0.1% DMSO]). The gray area represents the 95% prediction interval of the 0.1% DMSO data. Arrows indicate read-
outs that are expanded in 4C for closer inspection.
(C) Log expression ratios of selected readouts that show divergence between pan-PI3K inhibition and selective PI3K inhibition. Error bars indicate standard
deviation from triplicate samples.
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inherent variability of the assay, and is represented by the gray
shading surrounding log10 ratio = 0.0 in Figure 4 and Figure S3.
Effects of pan-PI3K Inhibition
The pan-PI3K inhibitor PIK90 elicited both anti-inflammatory and
antiproliferative effects. In conditions designed to mimic TH1-
driven endothelial cell-based inflammation (HUVECs stimulated
with IFNg, TNFa, and IL1b; Figure 4B, 3C), pan-PI3-K inhibition
showed a moderate effect on HUVEC viability (indicated by
a reduction in sulforhodamine B (SRB) protein binding < 0.3
log ratio) and inhibited HUVEC proliferation (Figure 4C). PIK90
also strongly inhibited the urokinase receptor (CD87/uPAR),
important in tissue remodeling (Solberg et al., 2001) and cell
motility (Kjoller and Hall, 2001), and HLA-DR, a surface receptor
important in antigen presentation to T cells (Rothbard et al.,
1988). In HUVECs stimulated with histamine and IL-4 (4H;
Figure 4B), the effects of PIK90 were more subtle, showing
onlymild inhibition of CD62/P-selectin, a cell adhesionmolecule.
When introduced to a PBMC/HUVEC coculture stimulated
with LPS, PIK90 exhibited little effect on cell viability but signifi-
cantly reduced CD40 and mildly reduced TNFa production
(Figures 4B and 4C; LPS). In PBMCs and HUVECs stimulated
with superantigen, PIK90 showed modest effects on E-selectin
(CD62), CCL2/MCP-1, and CD38 production, and a decrease
in PBMC (mostly monocytes and T cells) proliferation (Fig-
ure 4B; SAg). E-selectin is a cell-adhesion molecule expressed
by endothelial cells that recognizes sialylated sugars on leuko-
cytes, and is involved in the first stages of leukocyte recruitment
(McEver, 1991). CCL2/MCP-1 is a cytokine that recruits mono-
cytes to sites of injury (Daly and Rollins, 2003). Together, these
results suggest that pan-PI3K inhibitors reduce some parame-
ters associated with inflammation but exhibit general cytotox-
icity and decreased HUVEC proliferation. These effects may
significantly limit their utility for chronic conditions requiring
frequent administration.
Comparison of Selective PI3Kd and Selective
PI3Kd/ PI3Kg Inhibition
In contrast to the effects of pan-PI3K inhibition (PIK90), specific
inhibitors of PI3Kd (SW30) or PI3Kd/g (SW14) had effects on
inflammatory markers but little antiproliferative activity. SW30
and SW14 showed little effect on HUVECs stimulated with
inflammatory cytokines (Figure 4B; 3C, 4H), but were active in
suppressing markers of inflammation in cocultures of HUVEC
and PBMCs stimulated with LPS, the bacterial cell wall compo-
nent that binds Toll-like receptor 4, or superantigens, another
bacterial product which universally engages the T cell receptor
(TCR) (Figure 4B; LPS, SAg). The principal effect of the PI3Kd
selective compound SW30 occurred under superantigen stimu-
lated conditions (reduction of E-selectin expression (Figure 4C)
and PBMC proliferation) likely because the TCR, engaged by
superantigens, is coupled to PI3Kd (Okkenhaug et al., 2002;
Okkenhaug and Vanhaesebroeck, 2003). PBMC proliferation
decreased under the same conditions in response to SW30
and SW14, but they did not exhibit a toxic effect as read out
by Alamar blue reduction (PBMC cytotoxicity, Figure 4B), indi-
cating that they can inhibit PBMC growth without inducing cell
death. Together, these results suggest that PI3Kd inhibition isChemistry & Biology 17, 123more selective in exerting an anti-inflammatory profile than
a pan-PI3K inhibitor and may be particularly suited to treatment
of disorders with a dominant T cell component.
PI3Kd/g inhibition (SW14) was largely inactive in the HUVEC-
only culture conditions, only slightly decreasing proliferation at
the highest dose (10 mM; Figures 4B, 4C). In the LPS-stimulated
HUVEC/PBMC coculture, PI3Kd/g inhibition led to decrease of
TNFa production, more so than either PI3Kd inhibition (SW30)
or pan-PI3K inhibition (PIK90) (Figure 4C). When the HUVEC/
PBMC coculture was stimulated with superantigen, SW14
decreased proliferation and CCL2/MCP-1, CD38, and E-selectin
expression. An enhanced effect of PI3Kd/g inhibition was
observed: decreased monocyte TNFa production (under LPS
stimulation) and more efficacious (magnitude) inhibition of T cell
activation (E-selectin, PBMC proliferation; under superantigen
stimulation) (Figure 4C). Importantly, although SW14 inhibits
PI3Kb at below 1 mM (Figure 2B), related analogs (SW18, 19)
with 3-fold and 10-fold less PI3Kb inhibition, respectively
(Figure 2B; Figure S1) exhibited similar enhanced activity. The
profile of SW19 (Supplemental Information) also provides evi-
dence that the effects on TNFa are truly due to additional
PI3Kg activity, and not simply more potent PI3Kd inhibition.
SW19, though less potent on PI3Kd than SW30 (Figure 2B),
displays moderate activity against PI3Kg, which is enough to
exhibit the characteristic reduction of TNFa levels and cluster it
with SW14 and SW18, other PI3Kd/g dual inhibitors (Supple-
mental Information). The stronger monocyte and T cell inhibition
seen with PI3Kd/g inhibition may make these inhibitors particu-
larly effective in the treatment of inflammatory disorders driven
by TNFa.
Biological Activity of PI3K Inhibitors Relative
to Other Agents
Having defined a potential role for PI3Kd (SW30) in treatment of
T cell-mediated inflammatory diseases and PI3Kd/g (SW14) in
treatment of TNFa-mediated inflammatory disease, we sought
to put these agents in the broader context of approved anti-
inflammatory agents. We compared PI3K inhibitors with different
isoform selectivities to a panel of clinical and experimental com-
poundswith anti-inflammatory (cyclosporin A, prednisolone) and
anticancer activities. Included were CDK inhibitors (kenpaullone,
olomoucine, roscovitine), microtubule disruptors (vincristine,
colchicine), estrogens (17-b-estradiol, 2-methoxyestradiol),
HSP90 inhibitors (17-AAG, geldanamycin, radicicol), taxanes
(epithilone B, paclitaxel), p38 inhibitors (BIRB-796, VX-745),
IKK inhibitors (Ro106-9920, SC-514), JNK inhibitors (AS602801),
and mTOR inhibitors (everolimus, rapamycin) (Figure 5). The
profiles for each compound were analyzed using a Pearson
correlation metric and visualized in two dimensions through
a multidimensional scaling algorithm (Kunkel et al., 2004; Plavec
et al., 2004).
Compounds targeting PI3Kg and PI3Kd (SW14, SW18, SW30)
occupied a distinct space in this map. The more PI3Kd selective
compounds (SW30 and IC87114) clustered with lower doses
of the PI3Kd/g compounds, confirming our observations on
their specificity. Strikingly, compounds with significant activity
against PI3Kg (SW14, SW18) were functionally linked to the
glucocorticoid prednisolone, the active metabolite of predni-
sone. This result is supported by direct comparison of the–134, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 129
Figure 5. Function SimilarityMapof PI3K Inhibitors
and Other Compounds
A function similarity map of compounds from the SW
series with other anti-inflammatories, PI3K inhibitors, and
kinase inhibitors. This map is generated by subjecting
the pairwise correlation data of BioMAP profiles to multidi-
mensional scaling. Significant correlations are shown by
gray lines. The distance between the compounds is
inversely related to the similarity of their profiles. Com-
pounds are color coded, grouped by target class, and
the area of the circle is proportional to the dose.
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nificant similarities, especially with regard to their effect on
TNFa production in the LPS-stimulated HUVEC/PBMCcoculture
(Figure S3). Conversely, the pan-PI3K inhibitor (PIK-90), grouped
with other pan-PI3K inhibitors in a different region of the similarity
map (Figure 5) with inhibitors of their downstream target mTOR,
microtubule modulators, another downstream target of PI3K
(Onishi et al., 2007), and estrogens, which have been linked to
PI3Ks (Calippe et al., 2008; Simoncini et al., 2000).
A comparison of compounds that target the PI3K path-
way (Figure S4) showed that agents with significant PI3Ka
activity, including AS605240, clustered with inhibitors of mTOR.
AS605240, often described as a PI3Kg directed inhibitor,
showed significant similarity to the multitargeted inhibitors and
clustered with them, likely due to its activity against PI3Ka
(Figure S2; Supplemental Information).
DISCUSSION
We describe the design and synthesis of highly selective PI3K
inhibitors based on a quinazolinone scaffold that engages the
methionine switch observed in both PI3Kg (Knight et al., 2006)
and PI3Kd (Berndt et al., 2010). Elaboration of this scaffold
with aryl and alkyne affinity elements afforded compounds with
a wide range of activity against PI3Kd and PI3Kg but importantly
did not significantly inhibit PI3Ka, PI3Kb, or any of the 219 protein
kinases evaluated. These compounds were used in conjunction
with AS605240, a PI3Kg-directed literature inhibitor, and the
pan-PI3K inhibitor PIK90 in order to evaluate the effects of
isoform-selective inhibition in single and multicellular contexts.
Several PI3K inhibitors with different isoform selectivities were
tested in primary human cell models of inflammatory signaling.
Pan-PI3K inhibition (PIK90) was highly antiproliferative to both
HUVECs and PMBCs, whereas PI3Kd inhibition (SW30) or130 Chemistry & Biology 17, 123–134, February 26, 2010 ª2010 Elsevier Ltd All rightsPI3Kd/g inhibition (SW14) resulted in selective
T cell inhibition. Selective PI3Kd inhibition
(SW30) blocked T cell cytokine production, re-
sulting in decreased HUVEC E-selectin expres-
sion and revealing the potential to elicit a potent
anti-inflammatory response without a direct
effect on endothelial cells. Interestingly, SW30
and other selective PI3Kd inhibitors such as
IC87114 (Supplemental Information) did not
inhibit E-selectin expression in HUVECs directly
stimulated with IFNg, TNFa, and IL1b (3C;
Figure 4B), but only did so in the superantigen-stimulated HUVEC/PMBC coculture conditions (SAg; Figure 4B;
Supplemental Information). This result is consistent with these
compounds indirectly blocking E-selectin expression in HUVECs
as a result of lymphocyte TNFa production inhibition (TNFa is
known to rapidly upregulate E-selectin expression in HUVECs
[Schindler and Baichwal, 1994]), and these data clearly illustrate
the ability of these assays to capture parts of the intercellular
communication integral to inflammatory responses.
PI3Kd/g inhibition (SW14) was not cytotoxic to HUVECs and
displayed more significant anti-inflammatory effects in the
HUVEC/PBMC cocultures. Dual targeting of PI3Kd/g resulted in
enhanced inhibition of LPS-induced TNFa production (Figure 4C)
and overall T cell activation. The inhibitory effects observed with
inhibition of PI3Kd/g in these assays led us to wonder whether
they were due to synergistic inhibition of PI3Kd/g or whether
PI3Kg inhibition might be sufficient. The most commonly used
PI3Kg compound in the literature and only PI3Kg selective mole-
cule we were able to synthesize, AS605240, inhibits all PI3K iso-
forms at 300 nM (Camps et al., 2005), and primary human cell
assays displayed a profile similar to pan-PI3K compounds
(Figure S4; Supplemental Information).
Our studies using both new and benchmark compounds
show the most effective anti-inflammatory PI3K inhibitor is one
that inhibits both PI3Kd and PI3Kg. Pan-PI3K inhibitors, on the
other hand, demonstrated limited effects on anti-inflammatory
markers in T cell and monocyte-driven environments with con-
current antiproliferative effects. Nevertheless, it remains pos-
sible that selectively inhibiting other combinations of PI3K iso-
forms, such as PI3Ka/b, PI3Kb/g, or PI3Kb/d, may also show
synergistic anti-inflammatory activity.
Interestingly, additional inhibition of PI3Ka and b (PIK90) did
not further suppress inflammatory markers (Figure 4B; LPS,
SAg). In fact, when comparing the effects on E-selectin expres-
sion (SAg), selective inhibition of PI3Kd alone was better thanreserved
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tive (Figure 4C). The most effective isoform combination at inhi-
bition of LPS-induced TNFa production was also PI3Kd/g
(Figure 4C). Additional PI3Ka/b inhibition (PIK90), in addition to
displaying undesirable antiproliferative properties, did not signif-
icantly decrease TNFa expression and was essentially identical
to selective PI3Kd inhibition (Figure 4C). These results together
suggest a possible role for PI3Kg in TNFa production.
Both kinase-dependent and kinase-independent routes exist
through which PI3Kg could regulate TNFa production. PI3Kg
interacts with phosphodiesterase 3B (PDE3B), regulating cyclic
AMP (cAMP) levels and activation of protein kinase A (PKA),
leading to increased heart contractility (Patrucco et al., 2004)
and was also linked to PDE4 (Kerfant et al., 2007). PDE4 is the
main cAMP hydrolyzing enzyme in immune cells, and has been
pursuedasa target forgeneratingnovel anti-inflammatories (Teix-
eira et al., 1997) that suppress LPS-induced TNFa production in
monocytes (Souness et al., 1996). Because PI3Kg is required
for PDE4 activity (Kerfant et al., 2007), PI3Kg inhibition may lead
to diminished PDE4 activity and explain the TNFa suppression.
However, the first link between PDEs and PI3Kg involved a scaf-
folding, non-catalytic effect (Patrucco et al., 2004) and the PDE4-
PI3Kg link was discovered in a PI3Kg KO mouse (Kerfant et al.,
2007), which has no functional PI3Kg suggesting that this route
may not involve the catalytic activity of PI3Kg.
TNFa is involved in several autocrine signaling loops (Lisby
et al., 2007) and it is possible that PI3Kg is involved in amplifying
such signals. TNFa activates PI3Kg in endothelial cells leading to
oxidant generation and NF-kB activation (Frey et al., 2006).
NF-kB regulates production of TNFa (Li and Stark, 2002) so
TNFamay activate its own production by NF-kB through PI3Kg.
TNFa can upregulate its own mRNA synthesis in keratinocytes
(Lisby et al., 2007), and if this happens in PBMCs, it provides an
attractive model for PI3Kg involvement in TNFa production and
may explain why PI3Kg inhibition lowers TNFa levels.
Our data suggest that inhibition of PI3Kg’s catalytic activity is
sufficient to regulate TNFa levels, but they do not necessarily rule
out other mechanisms. It is possible that application of BioMAP
analysis to this question may resolve the conflict. If the combina-
tion of a PDE4 inhibitor and a PI3Kg inhibitor did not alter TNFa
levels more than either inhibitor alone, this would suggest that
PI3Kg is signaling through PDE4; if, however, combined inhibi-
tion of PDE4 andPI3Kg further decreased TNFa levels, thismight
suggest that they work through independent pathways (as
mentioned above). Results obtained by treating with more than
one compound may be unreliable because of potential off-target
effects, thus a combination of a specific inhibitor with siRNA in
a BioMAP system might better resolve the dilemma.
Inbroad terms,PI3Ksignalingcanbeviewed into twodivisions,
a survival pathway (a/b) and inflammatory PI3K (d/g) pathway, yet
inhibitors that target bothunits can lead to functional antagonism.
Essentially, inhibition of class I PI3-Ks is not necessarily additive,
and inhibition of PI3-Ka and PI3-Kb can actually antagonize the
effects of more isoform selective inhibition. For example, inhibi-
tion of PI3Kd/g by SW14 results in suppression of E-selectin or
TNFa but additional inhibition of PI3Ka/b using PIK90 actually
results in a smaller degree of suppression (Figure 4B).
The actual mechanisms by which PI3Ka/b inhibition may
antagonize PI3Kd/g inhibition are not perfectly clear. In theChemistry & Biology 17, 123case of TNFa suppression, pan-PI3K inhibition with wortmannin
and LY294002 has been shown to reverse amlodipine-induced
inhibition of TNFa production in LPS-stimulated rat cardiomyo-
cytes (Li et al., 2009), and of more relevance, treatment of
PBMCs and THP-1 monocytes with the same compounds
increases LPS induced TNFa expression (Guha and Mackman,
2002). Both wortmannin and LY294002 have more activity
outside of the class PI3Ks than PIK90, (Knight et al., 2006; Knight
and Shokat, 2005), which may explain why PIK90 did not
increase TNFa levels, but our results with pan-PI3K inhibition
are not necessarily surprising. Studies with pan-PI3K inhibitors
cannot identify the actual isoforms responsible for the increase
in TNFa levels, but a recent study showed that p110a deficient
THP-1 monocytes display increased TNFa production when
stimulated by LPS, suggesting that PI3Ka inhibition is respon-
sible for the increase in TNFa production (Lee et al., 2007).
Together this evidence suggests that PI3Ka inhibition increases
TNFa production, while PI3Kd/g inhibition decreases TNFa
production, and when all isoforms are inhibited, both activities
are balanced, leaving TNFa levels unchanged, but if PI3Ka is
not inhibited (in the case of our PI3Kd/g inhibitors) then TNFa
levels will decrease.
This work illustrates how targeted chemical inhibition can
access information not available from genetic inactivation of
one or more PI3K isoforms, which is difficult to obtain because
these animals often suffer significant defects during develop-
ment. Furthermore, results obtained using targeted inhibitors
can be different from those obtained in animals with sustained
genetic inactivation (Knight and Shokat, 2007). PI3Kd/PI3Kg
knockout mice exhibited a more severe immune phenotype
than mice lacking either isoform alone, (Swat et al., 2006;
Webb et al., 2005) but the severity of that phenotype is likely
due to sustained absence of both PI3Kd and PI3Kg and may
not be duplicated with pharmacological treatment.
Many clinical anti-inflammatory agents function through
different targets yet all have the property of inhibiting immune
cell function while leaving nonimmune cells relatively unaffected.
We asked if the PI3Kd/g inhibitors exhibited this property and
which current anti-inflammatory agents they might resemble.
The most closely related profile was that of the glucocorticoid
receptor (GR) agonist prednisolone. It is interesting that a partic-
ular multicellular profile can be achieved through two distinct
mechanisms (kinase inhibition versus nuclear hormone receptor
activation). Although prednisolone is an effective anti-inflamma-
tory agent, there have been efforts to identify ‘‘dissociating GR
agonists’’ that separate anti-inflammatory from other GR effects
(bone loss, cardiovascular disease) that limit their long-term use
(Schaecke et al., 2007). The discovery that PI3Kd/g inhibition can
functionally mimic several anti-inflammatory features of prednis-
olone opens a new way to improve upon a proven class of anti-
inflammatories (GR agonists) while targeting completely different
enzymes, and could only have been realized through analysis of
this compound series on primary human cells.
Despite the related responses of prednisolone and PI3Kd/g
inhibitors, the similarities may be limited to the cell types
we analyzed. Cell types that have documented GR agonist
responses (macrophages, coronary artery cells) are not included
in our assays. The exceptionally broad cellular effects of GR
agonists would likely be distinguished from PI3Kd/g inhibitors if–134, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 131
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primary human cells provides a powerful early assessment of
differential inhibition of important signaling nodes (PI3Ks,
nuclear receptors, JNKs, calcineurin, IKK).
With the new availability of small molecules capable of inhibit-
ing the inflammatory PI3Ks (d/g) without inhibition of the ubiqui-
tous growth-linked PI3Ks, we are poised to begin to resolve the
opposing effects of pan-PI3K inhibition and selective inflamma-
tory PI3K inhibition and to begin further validation of PI3Kd/g as
a target for the treatment of inflammatory disorders.SIGNIFICANCE
The work describes the discovery of small-molecule inhibi-
tors of unusual potency and selectivity for immune cell-
expressed PI3Ks. Lipid kinases are emerging as critical
drug targets for a number of disease states. Although most
work has focused on anticancer properties of PI3K inhibi-
tors, here we address the two key challenges, one chemical
and one biological, in the development of isoform selective
inhibitors of PI3Kg and PI3Kd as a novel class of anti-inflam-
matory agents. The first challenge is how to selectively tar-
get PI3Kd and PI3Kg without inhibiting the ubiquitously
expressed PI3Ka and PI3Kb isoforms, which have nearly
identical ATP binding pockets. We address this challenge
by exploiting the first conformation specific binders to
PI3Kd and PI3Kg and develop the first panel of compounds
with differing profiles against these critical inflammatory
targets. The second challenge is determining which profile
of PI3K inhibition is desirable: completely selective PI3Kd
or PI3Kg inhibition, dual inhibition of PI3Kd and PI3Kg, or
possibly pan-PI3K inhibition. Although full or conditional
knockouts of each isoform have been generated in mice,
such model systems only provide a steady state loss-of-
function analysis. We therefore evaluated a panel of the
newly discovered PI3Kd/g inhibitors, along with benchmark
pan-selective inhibitors and a representative set of anti-
inflammatory agents with broad mechanism of action, in
primary human cocultures stimulated with proinflammatory
agents. The resulting map of anti-inflammatory drug action
reveals an unanticipated similarity between dual-PI3Kd/g
inhibitors and anti-inflammatory glucocorticoids. Impor-
tantly, our studies also show that inhibition of PI3Ks beyond
PI3Kd/g result in a decrease of some anti-inflammatory
effects, suggesting that pan-PI3K inhibitors will be less
immunosuppressive. These studies contribute both chemi-
cal and biological insights into the emerging area of PI3K
drug discovery for the treatment of inflammatory disease.EXPERIMENTAL PROCEDURES
Chemical Synthesis
All compounds were synthesized from commercially available starting mate-
rials, and purified by reverse-phase HPLC (MeCN:H2O:0.1% TFA). See
Supplemental Experimental Procedures for details.Kinase Assays
IC50s were determined as previously described (Knight et al., 2007). See
Supplemental Experimental Procedures for details.132 Chemistry & Biology 17, 123–134, February 26, 2010 ª2010 ElseTHP-1 Cell Culture
THP-1 monocytes (ATCC) were grown in RPMI-1640 media with 10% fetal
bovine serum (FBS), 0.004% beta mercaptoethanol (BME), and under 5%
CO2 at 300,000-500,000 cells/ml.THP-1 Signaling Assays
THP-1 monocytes were grown in serum-free RPMI-1640 with 0.004% BME
under 5% CO2 at 1,000,000 cells/ml for 4 hr, incubated with inhibitors or
DMSO for 10 min, and stimulated with 100 nM MCP-1 (R&D) for 5 min or
50 ng/ml CSF-1 (Peprotec) for 7 min. Cells were fixed with paraformaldehyde;
1 ml cold methanol was added, and cells were stored at20C overnight. Two
milliliters of PBS was added, and cells were spun, resuspended in 1 ml PBS
with 5% FBS (FACS Buffer), and stored at 4C. Buffer was aspirated, and
10 ml block solution was added. After 10 min, 30 ml Alexa-conjugated antibody
in FACS buffer (1/5 dilution) was added to cells. After 30 min, cells were resus-
pended in 2 ml PBS and spun. PBS was removed; cells were resuspended in
100 ml FACS buffer and read on the FACS.
Cell Culture
HUVEC were pooled from multiple donors, cultured according to standard
methods, and plated into microtiter plates at passage 4. PBMCwere prepared
from buffy coats from normal human donors according to standard methods.
Concentrations of agents added to confluent microtiter plates to build each
system: cytokines (IL-1b, 1 ng/ml; TNFa, 5 ng/ml; IFN-g, 20 ng/ml; IL-4,
5 ng/ml), activators (SAg, 20 ng/ml; histamine, 10 mM; or LPS, 2 ng/ml), and
leukocytes (PBMC, 75,000 cells/well).Compounds
Compounds were tested at the indicated concentrations. Compounds were
added 1 hr before stimulation of the cells, and were present during the whole
24 hr stimulation period (or longer for proliferation assays).Readout Measurements
The expression of many readouts was measured by cell-based enzyme-linked
immunosorbent assays (ELISAs). For the ELISAs, microtiter plates are treated,
blocked, and then incubated with primary antibodies or isotype control anti-
bodies (0.01–0.5 mg/ml) for 1 hr. After washing, plates were incubated with
a peroxidase-conjugated anti-mouse IgG secondary antibody or a biotin-
conjugated anti-mouse IgG antibody for 1 hr followed by streptavidin-HRP
for 30 min. Plates were washed and developed with TMB substrate and the
absorbance (OD) was read at 450 nm (subtracting the background absorbance
at 650 nm). Quantitation of TNFa and PGE2 was done using commercially
available kits according to the manufacturer’s directions. Proliferation of
PBMCs (T cells) was quantified by Alamar blue reduction. Proliferation of
adherent cell types was quantified by SRB staining.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, Biomap profiles,
and Supplemental Experimental Procedures, and can be found with this article
online at doi:10.1016/j.chembiol.2010.01.010.ACKNOWLEDGMENTS
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